Michael Polansky Unveils AI Model Trained on Living Human Skin Cells

Tech entrepreneur and investor Michael Polansky has introduced a pioneering biocomputational initiative that trains machine learning architectures on real-time biochemical metrics extracted from living human skin cells.

The system utilizes microfluidic bio-sensors to stream gene expression and cellular stress responses directly into transformer-based biological foundation models. By capturing cellular reactions to topicals, UV radiation, and targeted therapeutics, the framework predicts dermatological outcomes with unprecedented precision without relying on traditional synthetic proxies.

Industry experts emphasize that training models on viable biological substrates bridges the gap between digital drug discovery and clinical trials. Polansky venture aims to license the biological transformer API to pharmaceutical firms to accelerate non-invasive treatment formulation and personalized skincare regimens worldwide.